Healthcare Business Management Association - HBMA
Leading the Business of Healthcare Login
Coronavirus Disease (COVID-19) Coronavirus Disease (COVID-19) - HBMA Healthcare Business Management Association

Coronavirus Disease (COVID-19) Update

Share
05/18/2021

HBMA COVID-19 Federal Response Update

White House and Federal Agencies

  • President Biden announced the U.S. will send 20 million vaccine doses from Pfizer, Moderna and Johnson & Johnson to other countries. This allocation is in addition to 60 million doses of the AstraZeneca vaccine that the U.S. will send abroad once that vaccine receives emergency approval from the FDA.

Centers for Disease Control and Prevention (CDC) Updates

Economy, Vaccine, Testing and Treatment

  • This article summarizes studies that the CDC used to inform its decision to issue new guidance that says fully vaccinated people can significantly scale back when and where they wear face masks. This includes a study of health workers that shows the Moderna and Pfizer/BioNTech vaccines are 94 percent effective.
    • CDC Director Rochelle Walensky acknowledges that it will be difficult for some people to accept the scaled-back mask wearing guidance.
    • Director Walensky also pushed back against accusations that the CDC faced external pressure to issue the new mask guidance. 
    • Businesses can still impose their own mask-wearing requirements.
    • Despite the new CDC guidance, masks are still required on public transportation such as airplanes and trains.
  • NIAID Director Dr. Anthony Fauci believes it is safe for schools to fully reopen for in-person learning in the fall.
  • Sanofi announced positive phase two clinical trial results for its COVID-19 vaccine. The company is planning to begin phase three trials soon with the goal of receiving FDA emergency approval before the end of the year.
  • NIAID Director Dr. Anthony Fauci acknowledged how the COVID-19 pandemic exposed “undeniable” systemic racism regarding healthcare access and outcomes.
  • New research shows delaying a second dose of the Pfizer/BioNTech vaccine until 12 weeks after the first dose produces a larger antibody response than the current approach of a three-week delay between doses.
  • A new study shows both the Pfizer and Moderna vaccines were effective against two COVID-19 variants that first originated in the U.K. and South Africa, respectively.
  • New research on patients with long-term COVID-19 symptoms shows that these patients tend to be younger. The prevalence of long-term (sometimes called “long haul”) symptoms has prompted support for a 9/11-style registry of long haul COVID-19 patients.